Skip to main content
SpringerLink
Log in

Alemtuzumab/fingolimod/methylprednisolone

Unexpected high multiple sclerosis and lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Bernard-Valnet R, et al. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab. Multiple Sclerosis and Related Disorders 25: 216-218, Oct 2018. Available from: URL: http://doi.org/10.1016/j.msard.2018.08.006 - France

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab/fingolimod/methylprednisolone. Reactions Weekly 1719, 20 (2018). https://doi.org/10.1007/s40278-018-51575-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51575-5

Search

Navigation